JP6900500B2 - 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 - Google Patents

抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 Download PDF

Info

Publication number
JP6900500B2
JP6900500B2 JP2019551563A JP2019551563A JP6900500B2 JP 6900500 B2 JP6900500 B2 JP 6900500B2 JP 2019551563 A JP2019551563 A JP 2019551563A JP 2019551563 A JP2019551563 A JP 2019551563A JP 6900500 B2 JP6900500 B2 JP 6900500B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody according
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510081A (ja
Inventor
ロナルド・ブラッドリー・ディマットス
ジロン・ル
タン・イン
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2020510081A publication Critical patent/JP2020510081A/ja
Priority to JP2021099897A priority Critical patent/JP7227312B2/ja
Application granted granted Critical
Publication of JP6900500B2 publication Critical patent/JP6900500B2/ja
Priority to JP2023018535A priority patent/JP7532571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019551563A 2017-04-20 2018-04-16 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 Active JP6900500B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021099897A JP7227312B2 (ja) 2017-04-20 2021-06-16 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP2023018535A JP7532571B2 (ja) 2017-04-20 2023-02-09 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20
US62/487,550 2017-04-20
PCT/US2018/027718 WO2018194951A1 (en) 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021099897A Division JP7227312B2 (ja) 2017-04-20 2021-06-16 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2020510081A JP2020510081A (ja) 2020-04-02
JP6900500B2 true JP6900500B2 (ja) 2021-07-07

Family

ID=62111232

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019551563A Active JP6900500B2 (ja) 2017-04-20 2018-04-16 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP2021099897A Active JP7227312B2 (ja) 2017-04-20 2021-06-16 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP2023018535A Active JP7532571B2 (ja) 2017-04-20 2023-02-09 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021099897A Active JP7227312B2 (ja) 2017-04-20 2021-06-16 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP2023018535A Active JP7532571B2 (ja) 2017-04-20 2023-02-09 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用

Country Status (28)

Country Link
US (3) US10647759B2 (https=)
EP (1) EP3612559A1 (https=)
JP (3) JP6900500B2 (https=)
KR (2) KR102352670B1 (https=)
CN (2) CN117024583A (https=)
AR (1) AR111208A1 (https=)
AU (2) AU2018255221B2 (https=)
BR (1) BR112019018810A2 (https=)
CA (1) CA3058482C (https=)
CL (1) CL2019002922A1 (https=)
CO (1) CO2019011349A2 (https=)
CR (1) CR20190445A (https=)
DO (1) DOP2019000241A (https=)
EA (1) EA201992163A1 (https=)
EC (1) ECSP19075146A (https=)
IL (1) IL269003B2 (https=)
JO (1) JOP20190247A1 (https=)
MA (1) MA50144A (https=)
MX (2) MX2019012445A (https=)
NZ (1) NZ758066A (https=)
PE (1) PE20200011A1 (https=)
PH (1) PH12019502361A1 (https=)
SA (1) SA519410311B1 (https=)
SG (1) SG11201909022PA (https=)
TW (2) TWI705975B (https=)
UA (1) UA126806C2 (https=)
WO (1) WO2018194951A1 (https=)
ZA (2) ZA201906159B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI705975B (zh) * 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US20220177560A1 (en) 2019-03-26 2022-06-09 Janssen Pharmaceutica Nv Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
AR123688A1 (es) 2020-10-02 2023-01-04 Lilly Co Eli Métodos para reducir el contenido de proteínas de célula huésped en procesos de purificación de proteínas
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
CA3235104A1 (en) * 2021-10-22 2023-04-27 Kevin BIGLAN O-glcnacase (oga) inhibitor combination therapy
AR127484A1 (es) 2021-10-29 2024-01-31 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
CA3236560A1 (en) 2021-10-29 2023-05-04 Marcio Chedid Compounds and methods targeting interleukin-34
JP7823186B2 (ja) 2021-10-29 2026-03-03 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
IL320884A (en) * 2022-11-17 2025-07-01 Lilly Co Eli Anti-n3pglu amyloid beta antibodies, doses, and uses thereof
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025228316A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof
WO2025255300A1 (en) * 2024-06-06 2025-12-11 Eli Lilly And Company FORMULATIONS FOR ANTI-N3pGlu AMYLOID BETA ANTIBODIES
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026012421A1 (zh) * 2024-07-11 2026-01-15 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026075947A1 (en) 2024-10-01 2026-04-09 Eli Lilly And Company Dosing regimens for early alzheimer's disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
RU2011100127A (ru) 2008-06-12 2012-07-20 Аффирис Аг (At) Соединение, содержащее пептид, для лечения симптомов болезни паркинсона
CA2730073A1 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
PT3042917T (pt) * 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
PL3988117T3 (pl) * 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
TWI705975B (zh) * 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
CN110582511A (zh) 2019-12-17
TWI705975B (zh) 2020-10-01
KR102352670B1 (ko) 2022-01-19
US20200262902A1 (en) 2020-08-20
US20180305444A1 (en) 2018-10-25
AU2021203927A1 (en) 2021-07-08
KR102567295B1 (ko) 2023-08-16
JP7227312B2 (ja) 2023-02-21
JP7532571B2 (ja) 2024-08-13
AU2018255221B2 (en) 2021-07-01
TW201902924A (zh) 2019-01-16
PH12019502361A1 (en) 2020-07-13
ZA201906159B (en) 2026-03-25
JOP20190247A1 (ar) 2019-10-20
KR20220011800A (ko) 2022-01-28
MX2019012445A (es) 2020-01-13
US10647759B2 (en) 2020-05-12
WO2018194951A1 (en) 2018-10-25
ZA202007868B (en) 2023-06-28
UA126806C2 (uk) 2023-02-08
CN110582511B (zh) 2023-08-08
CR20190445A (es) 2019-11-06
IL269003A (en) 2019-10-31
AR111208A1 (es) 2019-06-12
SA519410311B1 (ar) 2022-03-20
MX2022011817A (es) 2022-10-10
NZ758066A (en) 2022-10-28
SG11201909022PA (en) 2019-11-28
IL269003B2 (en) 2025-10-01
ECSP19075146A (es) 2019-10-31
DOP2019000241A (es) 2019-10-15
CA3058482A1 (en) 2018-10-25
KR20190129100A (ko) 2019-11-19
US11078261B2 (en) 2021-08-03
MA50144A (fr) 2020-07-29
TWI789644B (zh) 2023-01-11
CA3058482C (en) 2023-05-09
BR112019018810A2 (pt) 2020-05-05
JP2023058623A (ja) 2023-04-25
CN117024583A (zh) 2023-11-10
EA201992163A1 (ru) 2020-03-02
CO2019011349A2 (es) 2019-10-31
AU2021203927B2 (en) 2024-03-21
PE20200011A1 (es) 2020-01-06
US20210371509A1 (en) 2021-12-02
TW202120541A (zh) 2021-06-01
IL269003B1 (en) 2025-06-01
AU2018255221A1 (en) 2019-09-19
CL2019002922A1 (es) 2020-03-13
JP2020510081A (ja) 2020-04-02
EP3612559A1 (en) 2020-02-26
JP2021151253A (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
JP7532571B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
AU2017207250B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
JP2024503724A (ja) 免疫調節抗体およびその使用
EA048806B1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение
BR122024022779A2 (pt) Molécula de ácido nucleico, célula de mamífero, processo para produzir um anticorpo anti-n3pg ab
BR112018011308B1 (pt) Anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210616

R150 Certificate of patent or registration of utility model

Ref document number: 6900500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250